RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases, today presented key findings related to lipoprotein particles (LDL-P) and cardiovascular disease at the Annual Meeting of the American Heart Association (AHA) in Los Angeles. Low density lipoprotein cholesterol levels (LDL-C) do not always provide an accurate assessment of overall heart health. LDL-P are also a key factor in cardiovascular disease (CVD) management. Elevated LDL-P cause plaque buildup in the arteries, which in turn leads to heart attacks and other CVD events. LDL-P is a key component of LipoScience’s NMR LipoProfile® test, which provides physicians and their patients with actionable information to personalize management of heart disease risk.